Hi, Biotech
Independent biotech publication (launched October 2026) focused on evidence-based coverage of vaccines, infectious disease, biomanufacturing, and biotech funding. Publishes a weekly briefing and maintains a republished historical press archive of prior R&D activity for research and archival purposes. Editorial content is sourced and fact-checked against primary documents including regulatory filings, trial registries, peer-reviewed literature, and company disclosures.
Industries
Nr. of Employees
small (1-50)
Patents
Products
GPI-0100
GPI-0100 is a saponin-based vaccine adjuvant utilized in several third-party clinical trials of prophylactic and therapeutic vaccine candidates and available for license.
Multivalent New World Alphavirus Vaccine Candidate
A multivalent vaccine candidate providing protection against Venezuelan, Eastern, and Western equine encephalitis viruses (VEEV, EEEV, and WEEV) with a single formulation.
Pan-Beta Coronavirus Vaccine Candidate
A pan-beta coronavirus (sarbecoviruses) vaccine candidate designed to provide protection against SARS-CoV-1, SARS-CoV-2, and MERS in a single formulation.
Ebola, Sudan, and Marburg Recombinant Glycoprotein Vaccines
Individual and multivalent filovirus vaccines developed using recombinant glycoproteins from Ebola virus, Sudan virus, and Marburg virus.
West Nile Vaccine
A recombinant subunit vaccine for West Nile virus developed by Hawaii Biotech, maintaining an IND and having completed Phase 1 human clinical studies.
Zika Virus Vaccine Candidate
A recombinant subunit Zika virus vaccine candidate optimized for rapid and durable immune responses and cross-reactivity with other flaviviruses.
GPI-0100
GPI-0100 is a saponin-based vaccine adjuvant utilized in several third-party clinical trials of prophylactic and therapeutic vaccine candidates and available for license.
Multivalent New World Alphavirus Vaccine Candidate
A multivalent vaccine candidate providing protection against Venezuelan, Eastern, and Western equine encephalitis viruses (VEEV, EEEV, and WEEV) with a single formulation.
Pan-Beta Coronavirus Vaccine Candidate
A pan-beta coronavirus (sarbecoviruses) vaccine candidate designed to provide protection against SARS-CoV-1, SARS-CoV-2, and MERS in a single formulation.
Ebola, Sudan, and Marburg Recombinant Glycoprotein Vaccines
Individual and multivalent filovirus vaccines developed using recombinant glycoproteins from Ebola virus, Sudan virus, and Marburg virus.
West Nile Vaccine
A recombinant subunit vaccine for West Nile virus developed by Hawaii Biotech, maintaining an IND and having completed Phase 1 human clinical studies.
Zika Virus Vaccine Candidate
A recombinant subunit Zika virus vaccine candidate optimized for rapid and durable immune responses and cross-reactivity with other flaviviruses.
Services
A concise weekly email briefing that summarizes and interprets major biotech stories relevant to vaccines, infectious disease, manufacturing and funding.
Online republication and organization of historical press releases, publications, and R&D notices for research and archival use.
A concise weekly email briefing that summarizes and interprets major biotech stories relevant to vaccines, infectious disease, manufacturing and funding.
Online republication and organization of historical press releases, publications, and R&D notices for research and archival use.
Expertise Areas
- Infectious disease reporting and analysis
- Vaccine development and regulatory interpretation
- Biotech funding and deal analysis
- Biomanufacturing and capacity coverage (CDMO / fill-finish)
Key Technologies
- Recombinant antigen production
- Subunit vaccine formulation
- Adjuvant-based vaccine formulation
- Hybridoma cell culture for antibody production
News & Updates
Weekly briefing explaining recent regulatory and commercial developments affecting dengue vaccines.
Analysis of Q3 2026 biotech venture funding, noting concentration of capital in a small number of companies.
Report on regulatory suspensions and market exits that affected dengue vaccine availability in 2026.
Coverage of regulatory approval milestones for mRNA influenza vaccines and implications for platform use beyond COVID-19.
Republished record of a 2001 peer-reviewed study evaluating recombinant dengue envelope proteins in a rapid immunochromatographic serological assay, with links to the original full text.
Republished government press release describing a Small Business Innovation Research (SBIR) matching grants program.
Weekly briefing explaining recent regulatory and commercial developments affecting dengue vaccines.
Analysis of Q3 2026 biotech venture funding, noting concentration of capital in a small number of companies.
Report on regulatory suspensions and market exits that affected dengue vaccine availability in 2026.
Coverage of regulatory approval milestones for mRNA influenza vaccines and implications for platform use beyond COVID-19.
Republished record of a 2001 peer-reviewed study evaluating recombinant dengue envelope proteins in a rapid immunochromatographic serological assay, with links to the original full text.
Republished government press release describing a Small Business Innovation Research (SBIR) matching grants program.